Bionano Genomics Inc (NASDAQ: BNGO)’s stock price has plunge by -8.98relation to previous closing price of 0.25. Nevertheless, the company has seen a -19.45% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-13 that Bionano Genomics, Inc. (NASDAQ:BNGO ) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants David Holmes – IR Erik Holmlin – CEO and Principal Financial Officer Conference Call Participants Sung Ji Nam – Scotiabank Destiny Hance – Ladenburg Thalmann Mark Massaro – BTIG Operator Good day, and welcome to the Bionano Third Quarter 2024 Earnings Conference Call. Today’s conference is being recorded.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
Company’s 36-month beta value is 2.34.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNGO is 101.34M, and currently, short sellers hold a 9.70% ratio of that floaft. The average trading volume of BNGO on November 18, 2024 was 2.15M shares.
BNGO’s Market Performance
BNGO stock saw a decrease of -19.45% in the past week, with a monthly decline of -32.79% and a quarterly a decrease of -56.73%. The volatility ratio for the week is 8.52%, and the volatility levels for the last 30 days are 10.09% for Bionano Genomics Inc (BNGO). The simple moving average for the past 20 days is -21.91% for BNGO’s stock, with a -69.31% simple moving average for the past 200 days.
Analysts’ Opinion of BNGO
Scotiabank gave a rating of “Sector Outperform” to BNGO, setting the target price at $4 in the report published on January 05th of the previous year.
BNGO Trading at -37.58% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.13% of loss for the given period.
Volatility was left at 10.09%, however, over the last 30 days, the volatility rate increased by 8.52%, as shares sank -29.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -49.24% lower at present.
During the last 5 trading sessions, BNGO fell by -18.77%, which changed the moving average for the period of 200-days by -79.83% in comparison to the 20-day moving average, which settled at $0.2869. In addition, Bionano Genomics Inc saw -88.15% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -3.24 for the present operating margin
- -0.01 for the gross margin
The net margin for Bionano Genomics Inc stands at -4.07. The total capital return value is set at -1.99. Equity return is now at value -161.77, with -100.85 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.31 points at debt to capital in total, while cash flow to debt ratio is standing at -4.31. The debt to equity ratio resting at 0.46. The interest coverage ratio of the stock is -21.53.
Currently, EBITDA for the company is -213.6 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 1.1. The receivables turnover for the company is 6.27for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.
Conclusion
In a nutshell, Bionano Genomics Inc (BNGO) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
